Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor

Melanoma and Skin Cancer

Risk Factors of Subsequent Primary Melanomas in Austria

JAMA Dermatol.

Müller C, Wendt J, Rauscher S, Sunder-Plassmann R, Richtig E, Fae I, Fischer G, Okamoto I

Melanoma and Skin Cancer

Mohs Micrographic Surgery for Primary Versus Recurrent or Incompletely Excised Facial High-risk Basal Cell Carcinomas

Acta Derm Venereol

Ceder H, Grönberg M, Paoli J

doi: 10.2340/00015555-3698

Melanoma and Skin Cancer

Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomised controlled trial

Br J Dermatol.

Dieng M, Morton RL, Costa DSJ, Butow PN, Menzies SW, Lo S, Mann GJ, Cust AE, Kasparian NA

doi: 10.1111/bjd.17990.

Melanoma and Skin Cancer

Statins may reduce disease recurrence in patients with ulcerated primary melanoma

Br J Dermatol.

von Schuckmann LA, Khosrotehrani K, Ghiasvand R, Hughes MCB, van der Pols JC, Malt M, Smithers BM, Green AC

doi: 10.1111/bjd.19012.

Melanoma and Skin Cancer

Non-Invasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma

J Invest Dermatol.

Ferris L, Moy R, Gerami P, Sligh JE, Jansen B, Yao Z, Cockerell CJ

doi: 10.1016/j.jid.2018.10.041.

Melanoma and Skin Cancer

Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma

JAMA Dermatol.

Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T

doi: 10.1001/jamadermatol.

Melanoma and Skin Cancer

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

Melanoma Res

Adams AM, Chick RC, Vreeland TJ, Clifton GT, Hale DF, McCarthy PM, O'Shea AE, Bohan PMK, Hickerson AT, Park H, Sloan AJ, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Wagner T, Faries MB, Peoples GE

doi: 10.1097/CMR.0000000000000758

Melanoma and Skin Cancer

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

Eur J Cancer

Eggermont AM, Meshcheryakov A, Atkinson V, Blank CU, Mandala M, Long GV, Barrow C, Di Giacomo AM, Fisher R, Sandhu S, Kudchadkar R, Ortiz Romero PL, Svane IM, Larkin J, Puig S, Hersey P, Quaglino P, Queirolo P, Stroyakovskiy D, Bastholt L, Mohr P, Hernberg M, Chiarion-Sileni V, Strother M, Hauschild A, Yamazaki N, van Akkooi AC, Lorigan P, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C

doi: 10.1016/j.ejca.2021.09.023

COMMENTED

Melanoma and Skin Cancer

High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk

Br J Dermatol.

Duffy DL, Lee KJ, Jagirdar K, Pflugfelder A, Stark MS, McMeniman EK, Soyer HP, Sturm RA

doi: 10.1111/bjd.17833.

Related content

Risk Factors of Subsequent Primary Melanomas in Austria

Mohs Micrographic Surgery for Primary Versus Recurrent or Incompletely Excised Facial High-risk Basal Cell Carcinomas

Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomised controlled trial

Statins may reduce disease recurrence in patients with ulcerated primary melanoma

Non-Invasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma

Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk